Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in vitro drug resistance profiling studies with...
Main Authors: | Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3797783?pdf=render |
Similar Items
-
7-step flow synthesis of the HIV integrase inhibitor Dolutegravir
by: Ziegler, Robert E., et al.
Published: (2020) -
Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
by: Horacio Gil, et al.
Published: (2022-12-01) -
Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
by: Linda A. Mandikiyana Chirimuta, et al.
Published: (2022-10-01) -
Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
by: Kaiming Tao, et al.
Published: (2023-09-01) -
HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis.
by: Ezechiel Ngoufack Jagni Semengue, et al.
Published: (2022-01-01)